Jacob M Hands
Researcher in integrative medicine and nutrition science, trained at George Washington University, who wrote a cautious review of whether off-label rapamycin is justified for healthy adults
Department of Pathology, University of Southern California (2026 paper) · earlier at the George Washington University School of Medicine and Health Sciences (2025)
Jacob Hands was first author of a 2025 review in Aging (HAN2025) that asked a direct question: what does the human evidence say about taking low-dose rapamycin, or related mTOR-blocking drugs, to slow aging in healthy adults? Some people already take rapamycin off-label for this reason, based mostly on animal studies in which it lengthened life. The review collected the clinical studies and re-analysed one group of people using PhenoAge, a 'biological age' score calculated from routine blood tests.
Its verdict was careful. The animal data on lifespan are strong, but the human studies are small, short and use different doses and measures, and they have not shown that rapamycin slows aging in healthy people. The review is useful as a reminder of the gap between results in mice and evidence in people.
PubMed lists Hands at the George Washington University School of Medicine and Health Sciences on the 2025 review. A 2026 narrative review in Nutrients, on common genetic variants that affect blood fats and heart disease risk and how diet might interact with them, lists Hands at the Department of Pathology of the University of Southern California, with co-authors from George Washington University's Office of Integrative Medicine and Health. No personal page was found to confirm job title or training.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2025 | R | What is the clinical evidence to support off-label rapamycin therapy in healthy adults? HAN2025 First author: reviewed the human evidence for off-label rapamycin in healthy adults and concluded that it does not yet show a slowing of aging. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Jacob M Hands.
ShowHide
- Bradley Rosen Los Angeles physician, originally trained as a retina specialist, who runs a longevity-medicine practice built around rapamycin and metformin, and senior author of a cautious review of the human evidence for off-label rapamycin in healthy adults
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.